# NHS National Generic Pharmaceuticals - Lenalidomide

> Contract award record from UK public-sector procurement sources.

## Key facts

- Public buyer: [NHS England](/buyers/nhs-england/contract-awards)
- Contract winner: Mercury Pharmaceuticals Limited
- Award value: £1
- Tender value: £26,345,313
- Award date: 31 August 2022
- Published: 30 September 2022
- Contract start: 1 September 2022
- Contract end: 31 August 2023
- Stage: awarded
- Procurement category: goods
- Notice ID: b76ce98c-f644-4e5a-af83-617f769811a4-576781
- OCID: ocds-b5fd17-217bd3c1-6e85-44b0-8f07-cd2ff7d988b7

## Description

Invitation to offer for NHS National Generic Pharmaceuticals - Lenalidomide Offer reference number: CM/PHG/21/5638 Period of framework agreement: 01/09/2022 to 31/08/2023 \(12 months\) with an option or options to extend \(at the Authority's discretion\) for a period or periods up to a total of 48 months\. Potential periods of call-offs under the framework agreement: Lenalidomide: ALL REGIONS: 01/09/2022 to 31/08/2023 \(12 months\)

## Related contract awards

- [OutSystems licenses for MAPPTI \(AP&P\)](/contracts/ocds-b5fd17-521fbf90-6e93-4366-b3bc-47aa2efd447d): NHS England
- [Provision of national e-portfolio 26/27](/contracts/ocds-b5fd17-7e027849-39ea-4eb8-8eb0-3b38f18dcca4): NHS England
- [D&A Platform Run & Maintain](/contracts/ocds-b5fd17-58fe109d-49a3-4eea-957d-31f6bd69ff81): NHS England
- [NHS Framework Agreement-Branded Medicines - National Proprietary Pharmaceuticals](/contracts/ocds-b5fd17-f3419ee6-884e-4ba4-9f88-cdfcb350ba4e): NHS England
- [NHS National Pharmaceuticals Transition 2021\_3](/contracts/ocds-b5fd17-d87b195f-23f2-4420-b141-6d1b0d6ffb05): NHS England

## Source

[View the original notice on Contracts Finder](https://www.contractsfinder.service.gov.uk/Notice/b76ce98c-f644-4e5a-af83-617f769811a4-576781)